In an analyst call, Merck EVP and CFO Peter Kellogg said the
company plans “continued DTC efforts for Singulair and Januvia as well as
appropriate promotional support for Gardasil, RotaTeq and Zostavax,” along with
support for the launch of Isentress and hopeful Cordaptive.